Clear Street on Enliven Therapeutics (ELVN): MRK's TERN acquisition 'sharpens investment case for ELVN-001'
Tweet Send to a Friend
Clear Street analyst Kaveri Pohlman reiterated a Buy rating and $36.00 price target on Enliven Therapeutics (NASDAQ: ELVN)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
